PI Industries: ₹1,611 Cr Profit with 28% OPM – Agrochemical Shaolin of Gujarat
1. At a Glance
PI Industries is the kind of stock that eats volatility for breakfast and still manages to maintain its 28% operating margin diet. With a market cap of ₹58,000+ Cr, it runs one of the cleanest, debt-lightest chemical balance sheets in India. The latest Q1 FY26 results show ₹1,900 Cr in revenue, ₹400 Cr in PAT, and more confidence than a startup founder with Series D funding and zero EBITDA.
2. Introduction
Let’s cut the crop and get to the chemicals. PI Industries is no meme stock, no overnight “green hydrogen” moonshot. It’s a disciplined, research-heavy, export-powered agrochemical ninja that’s spent the last decade compounding earnings and quietly becoming the McKinsey of contract manufacturing.
PI’s global CRAMS business (Contract Research and Manufacturing Services) is what truly drives the magic. While the domestic agrochem market stumbles with rain tantrums and subsidy politics, PI keeps bottling molecules for global agro giants like it’s breaking bad legally.
Sure, Q1 FY26 saw an 8% revenue drop, but pharma CRAMS shot up 186%. It’s like watching your opener get out for a duck, and your middle order hit a double century. Welcome to PI Industries — where margin preservation is a religion, and expansion is an art form.
3. Business Model (WTF Do They Even Do?)
PI Industries runs a dual-engine model:
Domestic Agri-Formulations – Herbicides, fungicides, insecticides under owned brands.
Custom Synthesis/CRAMS – Long-term contracts with global agro and pharma majors to manufacture high-value molecules.
The CRAMS segment now contributes over 60% of revenue, and is what gives PI its defensive growth vibe. Think high entry barriers, decade-long relationships, tech transfer, and molecule manufacturing that’s not easily replicated.
R&D spend is consistently high, and with 40+ patents and multiple molecules in the pipeline, it’s not just manufacturing — it’s co-developing the future of crop and pharma chemistry.
4. Financials Overview
Here’s the cocktail of numbers, stirred not shaken:
TTM Revenue: ₹7,809 Cr
TTM EBITDA: ₹2,115 Cr (Margin: 27%)
TTM Net Profit: ₹1,611 Cr
EPS (TTM): ₹106.21
Stock P/E: 3,838 / 106.21 = ~36.1x
ROCE: 22.9%
ROE: 17.6%
Even with TTM profit down 8% YoY, this is elite stuff. Most companies can only dream of these margins and consistency while fighting capex, weather, and currency swings.
5. Valuation – Fair Value Range
Method
Calculation
FV (₹)
P/E
35 × EPS ₹106.21
3,717
EV/EBITDA
EV ₹56,000 Cr ÷ EBITDA ₹2,115 = 26.4x
3,550
DCF
18% EPS CAGR, 10% discount rate
4,100
Fair Value Range: ₹3,550 – ₹4,100
“This FV range is for educational purposes only and is not investment advice.”
6. What’s Cooking – News, Triggers, Drama
Q1 FY26 PAT ₹400 Cr, flat YoY, but margins at 27%.
Pharma CRAMS growth: +186% — they’re scaling new verticals.
Capex Continues: ₹1,400+ Cr in FY25 alone; building
